OKLAHOMA CITY – Women considering hormone replacement therapy may have new options to discuss with their doctors after the U.S. Food and Drug Administration eased several major safety warnings on hormone products, according to Dr.Lacy Anderson.
Dr. Anderson says the FDA recently removed several “black box” warnings, which are the agency’s most serious safety notice, from many hormone replacement therapy products for women. Those warnings previously highlighted increased risks of cardiovascular disease, breast cancer and dementia, the FDA said.
Dr. Anderson said regulators reviewed updated scientific evidence and found the original warnings did not apply equally to every hormone formulation or to all groups of women. The FDA said the goal of the change is to improve access to hormone therapy for women managing postmenopausal symptoms, including hot flashes, mood swings and insomnia…